US: AKBLF - ALK-Abelló A/S

Rentabilidade por seis meses: +46.12%

Cronograma de promoção ALK-Abelló A/S


Sobre a empresa

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.

Mais detalhes
It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета dkk
Сайт https://www.alk.net
Цена ао 27.03
Alteração de preço por dia: 0% (27.0328)
Alteração de preço por semana: +9.89% (24.6)
Alteração de preço por mês: +24.69% (21.68)
Alteração de preço em 3 meses: +33.17% (20.3)
Mudança de preço em seis meses: +46.12% (18.5)
Mudança de preço por ano: +137.13% (11.4)
Mudança de preço em 3 anos: -94.45% (487)
Mudança de preço em 5 anos: -87.8% (221.5)
Mudança de preço em 10 anos: 0% (27.0328)
Mudança de preço desde o início do ano: +137.13% (11.4)

Subestimação

Nome Significado Nota
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Eficiência

Nome Significado Nota
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 1 10
Total: 1.61

Obrigação

Nome Significado Nota
Debt/EBITDA 0 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 47.34 6
Rentabilidade Ebitda, % 268.55 10
Rentabilidade EPS, % -833.33 0
Total: 3.2

Supervisor Cargo Pagamento Ano de nascimento
Mr. Claus Steensen Solje Executive VP, CFO & Member of Management Board 1972 (52 ano)
Mr. Søren Daniel Niegel Executive VP of Commercial Operations & Member of Management Board 1971 (53 ano)
Dr. Henriette Mersebach Executive VP Research & Development & Member of Management Board 1971 (53 ano)
Ms. Katja Barnkob Thalund Project Director of Global CMC Development & Employee-elected Director 1969 (55 anos)
Ms. Lise Lund Maerkedahl Project Director of Global Research & Employee-elected Director 1967 (57 anos)
Mr. Peter Halling President & CEO 1977 (47 anos)
Mr. Per Plotnikof VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
Prof. Hendrik Kees Kam Nolte M.D., Ph.D. Senior Vice President of Research & Development - North America and International Markets
Mr. Christian G. Houghton Head of Product Supply
Mr. Peter Sejer Andersen Senior Vice President of Global Research & Drug Discovery

Endereço: Denmark, Horsholm, BOege AllE 6-8 - abrir no Google Maps, abrir mapas Yandex
Site: https://www.alk.net